Member Info for 54retiresoon

Reminder from a question I posed to the Head of Biology over lunch at the AGM "how easy is it to manipulate a drug so that it has the correct chemistry to bind to the Pre|CISION substrate? Answer - it's very easy you just need to be sure that the addition does not change the actions of the drug.

Answer not in quotes as I did not immediately write down word for word what he said but you get the gist.

Does not get my vote - 100x and I might consider it and then say neh.

From https://medtechintelligence.com/feature_article/reshaping-of-the-biotech-ma-landscape/

"While the road ahead might be unpredictable, the core dynamics of the life sciences sector and the coming expiry of patents worth over $100 billion are poised to drive a renaissance in biotech mergers and acquisitions."

You have an oncology drug with $5bn annual sales with lots of nasty side effects coming off patent in 3 years time. How much is a licensing deal with Avacta worth to produce a prodrug version with a brand new patent, limited side effects and therefore potential for higher price and greater sales?

The clocks ticking the cliff is approaching.

Avacta has the potential to sign 5-10 such licensing deals once data hits if no one steps in to take the whole pie.

Know the value to Big Pharma of what you hold.

What could we possibly look forward to next week with the AACR conference taking place? I had a dream.

Monday 9th - AM RNS with results for first six cohorts and quotes from Dr William Tap about how great it is. PM RNS as FDA approve AVA6000 for STS with immediate with 3 week dosing.

Tuesday 10th - 1st licensing deal announced for Precision to be applied to a Big Pharma's existing drug to improve efficacy and remove patent cliffhang. Worth billions with tens of millions upfront plus a take up of 10 million new shares at a significant mark-up to current share price.

Wednesday 11th - 2nd licensing deal announced for a partnership with Big Pharma to take AVA6000 through Phase 2 trails for indications other than STS. Worth billions with £100 million upfront plus a take up of 10 million new shares at a significant mark-up to current share price.

Thursday 12th - 3rd licensing deal announced in respect of a Big Pharma company to use Precision to resurrect a drug discontinued due to its high toxicities. Worth billions with tens of millions upfront plus a take up of 10 million new shares at a significant mark-up to current share price.

Friday RNS - Heights have issued a notice of conversion for some of the principal to be repaid and Avacta confirm that it has been paid in cash.

How about a data release early next week to really get them flocking around? Or is it an opportunity to ink the first licensing deal?

Not forgetting Affimers also work.

From the RNS

"our lead asset AVA6000 continues to advance through the clinic at pace."

"The data to be presented showcases the potential of our two therapeutic platforms to generate further high value clinical assets."

"AVA3996, demonstrates targeted killing of cancer cells in vitro and, by concentrating the active warhead in the tumour, reduces systemic toxicity associated with this class of drug."

"AVA032, displays encouraging efficacy when tested in multiple models of immunomodulation, stimulating a potent immune response and reversing the immunosuppressive tumour microenvironment."

I thought it was poor from a "financial analyst". Sell on data release!!!

AVA6000 works it's in the RNS -

Avacta's lead pre|CISION™ programme, AVA6000, a tumour microenvironment activated ... cf.

Preclinical data regarding AVA3996, the second pre|CISION™ programme, a tumour targeted ...

You could not say activated if you did not have proof that it activated i.e. 9/9 biopsies plus all the data from 40 patients.

We have 12 months+ cash and data release in Q4 seals as many licensing deals as Avacta want from Big Pharma to improve the safety profile and extend the patents of their existing chemo drugs or resuscitate drugs developed and abandoned because of their very high toxicity.

The other unknown is when do the FDA fast track approval for AVA6000. Given the quantum leap compared to Dox and Dr. Tap the leading STS clinician I would not be surprised for approval before they have got far with the 2 week trial. Surely its a no brainer to allow STS patients to receive 3 weekly doses while they ascertain if 2 weeks might be more beneficial instead of just giving them straight dox.

Q4 starts tomorrow and the clock is ticking.

I spoke to the Head of Biology during lunch at the AGM in front of the AVA3996 poster. I asked how easy it was to alter any drug to have the correct chemistry to be able to link with precision. Answer - not difficult just need to check that the modification does not change how the drug works. Any drug designed for a high in FAP cancer type could be improved by Precision.

I would disagree on point 6.

It is better for mankind for Avacta to retain Precision and licence it out to numerous BP to improve their existing drugs or resurrect those which were discontinued as too toxic than for one BP to take control of Precision and control the chemo market.

Value could rapidly rise on license deals and on fast track approval for AVA6000 in STS during the short study by FDA.

Dr Craig Williams

(DILLIGAF)

out of network3rd+

🇺🇦Supporting Welsh Aid For Ukraine 🇺🇦 A group sourcing and transporting medical equipment to Ukraine.

3d

(edited)

Truly excellent news. 👏👏👏👏👏👏

Worth pointing out that AVA 6000 can be given by a simple IV cannula in the back of the hand.

Avoiding the insertion time, difficulties, and constant reminder of the disease that a central line involves.

This is huge. Absolutely huge.

https://www.cancerresearchuk.org/about-cancer/treatment/chemotherapy/how-you-have/into-your-vein/central-lines

We started Monday at 114, we start Wednesday at 130 (just a 14% rise with an amazing RNS and interview plus follow up RNS). The Precision platform will be worth tens of billions within 24 months. Avacta is valued at £360m. Hold for as long as you can, this is a once in a lifetime opportunity.

Not surprised I am expecting someone who has previously worked with Shaun Chilton to get the job - hopefully find out Monday.

It was mentioned by Alastair at the AGM day in the auditorium that 1b would focus on STS but they could perhaps get a partner on board to fund a trial of AVA6000 on breast cancer.

Question posed to AS was is chance of success at least 50%, answer Yes. In my book on all we know about Dox and trial results so far the chance of success is close to 100%. Dox is standard of care for STS and AVA6000 is clearly better than dox on results given so far (more dox in tumour, less side effects).

When there are excessive sellers or shorter in the market this represents a great opportunity for the long term investor to grab a bargain. I have been invested in Avacta since January 2020 and have had opportunities to buy at reduced prices through selling by IP Group, shorters who drove the price down to 40p and Heights Capital selling off their awarded shares. The Precision platform works it delivers chemo direct to the tumour at multiples of the standard drug with much reduced side effects. It is a game changer in treatment worth tens of billions to whoever owns the technology and multiple billions to anyone who licenses it. Happy to add at 89p on Friday. Thanks Heights for making it possible.

Remember it is easy to modify a chemo drug so that it has the chemistry that will bind to the pre|CISION™ substrate - confirmed in discussions over lunch after AGM. Just need to ensure that the modification does not affect chemo drugs properties.

Andrew Saunders said that there were 7 STS patients in cohorts 3-5.

We have to remember the bar to be better than Doxorubicin is very low for STS. We know that side effects under AVA6000 are very much reduced. Average Progression Free Survival with Dox on STS was confirmed by Dr Tap at Science Day as 4.6 months - once dox stops being given for STS cancer usually starts growing and can only have a maximum of six cycles of standard dox. Match that PFS and you become standard of care. Obviously expecting to go well beyond that with higher more targeted doses for longer.

What we had confirmed at the AGM AVA6000 releases standard dox into the tumour, already seeing improvement in the quality of patients lives, response from dox known in 3-4 cycles but most stop after 2 cycles due to toxicities.

Dr Tap said at Science Day "if I have a doxorubicin that works better than standard dox overnight that becomes standard of care".

How far into Phase 1b will Dr Tap be breaking down the door of the FDA to get this approved for STS.